Noramco planning formulation tech unit alongside opioid API business

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Active pharmaceutical ingredients, Active ingredient, Pharmacology, Morphine

Former J&J controlled substance API unit Noramco is to rejig its business to cater for branded and generic drug firms and companies looking for formulation tech solutions.

Noramco – which was acquired by private equity investor SK Capital last year​ – outlined its plan this week, also explaining that it wants to expand its geographic reach.

The firm gave few details of what it intends to do but did say that, in addition to making active pharmaceutical ingredients (APIs), it plans to “serve as a provider of technology solution​,” citing its expertise in bioavailability, stability and ingredient purity as examples.

Bill Grubb, vice president of global business development, said: “Noramco is repositioning the company to serve as an innovation partner to the pharmaceutical industry, while still focusing 100% on the API market.

Every material we make and every technology solution we provide will be designed to solve problems and accelerate customers’ commercial projects. This will happen at an accelerated pace with additional focus on geographic expansion into emerging markets​.”

The firm also announced it will showcase novel technology for efficient synthesis of cannabinoid-based APIs at DCAT week in New York, US later this month.

SK bought Noramco along with affiliate Tasmanian Alkaloids, a grower and processor of opium poppies that are used to make ingredients for pain medications.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Related suppliers

Follow us


View more